These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33289590)

  • 1. Methylomic Signatures of High Grade Serous Ovarian Cancer.
    Cardenas H; Fang F; Jiang G; Perkins SM; Zhang C; Emerson RE; Hutchins G; Keer HN; Liu Y; Matei D; Nephew K
    Epigenetics; 2021 Nov; 16(11):1201-1216. PubMed ID: 33289590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
    Silva R; Glennon K; Metoudi M; Moran B; Salta S; Slattery K; Treacy A; Martin T; Shaw J; Doran P; Lynch L; Jeronimo C; Perry AS; Brennan DJ
    Int J Cancer; 2023 Jul; 153(1):120-132. PubMed ID: 36883413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.
    Tomar T; Alkema NG; Schreuder L; Meersma GJ; de Meyer T; van Criekinge W; Klip HG; Fiegl H; van Nieuwenhuysen E; Vergote I; Widschwendter M; Schuuring E; van der Zee AGJ; de Jong S; Wisman GBA
    BMC Med; 2017 Jun; 15(1):116. PubMed ID: 28641578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.
    Dai W; Zeller C; Masrour N; Siddiqui N; Paul J; Brown R
    Clin Cancer Res; 2013 Oct; 19(20):5788-5797. PubMed ID: 23965899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
    Reid BM; Vyas S; Chen Z; Chen A; Kanetsky PA; Permuth JB; Sellers TA; Saglam O
    BMC Cancer; 2021 Jun; 21(1):714. PubMed ID: 34140011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior.
    Reyes HD; Devor EJ; Warrier A; Newtson AM; Mattson J; Wagner V; Duncan GN; Leslie KK; Gonzalez-Bosquet J
    Sci Rep; 2019 Nov; 9(1):17996. PubMed ID: 31784612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic Targeting of Adipocytes Inhibits High-Grade Serous Ovarian Cancer Cell Migration and Invasion.
    Tang J; Pulliam N; Özeş A; Buechlein A; Ding N; Keer H; Rusch D; O'Hagan H; Stack MS; Nephew KP
    Mol Cancer Res; 2018 Aug; 16(8):1226-1240. PubMed ID: 29759990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
    Song F; Li L; Zhang B; Zhao Y; Zheng H; Yang M; Li X; Tian J; Huang C; Liu L; Wang Q; Zhang W; Chen K
    Gynecol Oncol; 2020 Jul; 158(1):178-187. PubMed ID: 32362568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.
    Bonito NA; Borley J; Wilhelm-Benartzi CS; Ghaem-Maghami S; Brown R
    Clin Cancer Res; 2016 Jun; 22(12):3097-3104. PubMed ID: 26763252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
    Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
    Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.
    Fang F; Cardenas H; Huang H; Jiang G; Perkins SM; Zhang C; Keer HN; Liu Y; Nephew KP; Matei D
    Cancer Res; 2018 Feb; 78(3):631-644. PubMed ID: 29229600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation-based profiling reveals distinct clusters with survival heterogeneity in high-grade serous ovarian cancer.
    Wang J; Li J; Chen R; Yue H; Li W; Wu B; Bai Y; Zhu G; Lu X
    Clin Epigenetics; 2021 Oct; 13(1):190. PubMed ID: 34645493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
    Lo Riso P; Villa CE; Gasparoni G; Vingiani A; Luongo R; Manfredi A; Jungmann A; Bertolotti A; Borgo F; Garbi A; Lupia M; Laise P; Das V; Pruneri G; Viale G; Colombo N; Manzo T; Nezi L; Cavallaro U; Cacchiarelli D; Walter J; Testa G
    Genome Med; 2020 Oct; 12(1):94. PubMed ID: 33121525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
    Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.
    Montavon C; Gloss BS; Warton K; Barton CA; Statham AL; Scurry JP; Tabor B; Nguyen TV; Qu W; Samimi G; Hacker NF; Sutherland RL; Clark SJ; O'Brien PM
    Gynecol Oncol; 2012 Mar; 124(3):582-8. PubMed ID: 22115852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
    Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
    Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
    Morden CR; Farrell AC; Sliwowski M; Lichtensztejn Z; Altman AD; Nachtigal MW; McManus KJ
    Gynecol Oncol; 2021 Jun; 161(3):769-778. PubMed ID: 33714608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of DNA Methyltransferase 3B Isoforms Is Associated with DNA Satellite 2 Hypomethylation and Clinical Prognosis in Advanced High-Grade Serous Ovarian Carcinoma.
    Del Castillo Falconi VM; Díaz-Chávez J; Torres-Arciga K; Luna-Maldonado F; Gudiño-Gomez AA; Pedroza-Torres A; Castro-Hernández C; Cantú de León D; Herrera LA
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
    Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
    Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression.
    Keita M; Wang ZQ; Pelletier JF; Bachvarova M; Plante M; Gregoire J; Renaud MC; Mes-Masson AM; Paquet ÉR; Bachvarov D
    Gynecol Oncol; 2013 Feb; 128(2):356-63. PubMed ID: 23219462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.